company background image
MDNA

Medicenna Therapeutics TSX:MDNA Stock Report

Last Price

CA$1.67

Market Cap

CA$94.0m

7D

56.1%

1Y

-57.5%

Updated

27 Jun, 2022

Data

Company Financials +
MDNA fundamental analysis
Snowflake Score
Valuation1/6
Future Growth5/6
Past Performance0/6
Financial Health4/6
Dividends0/6

MDNA Stock Overview

Medicenna Therapeutics Corp., an immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases.

Medicenna Therapeutics Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Medicenna Therapeutics
Historical stock prices
Current Share PriceCA$1.67
52 Week HighCA$4.55
52 Week LowCA$0.98
Beta0.43
1 Month Change29.46%
3 Month Change3.09%
1 Year Change-57.51%
3 Year Change10.60%
5 Year Change-14.36%
Change since IPO-38.15%

Recent News & Updates

Shareholder Returns

MDNACA BiotechsCA Market
7D56.1%14.4%0.1%
1Y-57.5%-31.0%-2.6%

Return vs Industry: MDNA underperformed the Canadian Biotechs industry which returned -24.3% over the past year.

Return vs Market: MDNA underperformed the Canadian Market which returned -4% over the past year.

Price Volatility

Is MDNA's price volatile compared to industry and market?
MDNA volatility
MDNA Average Weekly Movement12.2%
Biotechs Industry Average Movement11.0%
Market Average Movement10.0%
10% most volatile stocks in CA Market17.3%
10% least volatile stocks in CA Market4.4%

Stable Share Price: MDNA is not significantly more volatile than the rest of Canadian stocks over the past 3 months, typically moving +/- 12% a week.

Volatility Over Time: MDNA's weekly volatility (12%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
201718Fahar Merchanthttps://www.medicenna.com

Medicenna Therapeutics Corp., an immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases. Its lead product is MDNA55, an interleukin- 4 (IL-4) EC that has completed Phase IIb clinical trial for the treatment of recurrent glioblastoma, as well as preclinical and clinical development stages for the treatment of other brain and non-brain tumors. The company also develops MDNA11, an enhanced version of IL-2 to activate and proliferate the immune cells needed to fight cancer; MDNA209, an IL-2 antagonist for autoimmune diseases, such as multiple sclerosis and graft versus host disease; MDNA413, a dual IL-4/IL-13 antagonist to treat cancer immunotherapies; and MDNA132, an IL-13 Superkine for solid tumors.

Medicenna Therapeutics Fundamentals Summary

How do Medicenna Therapeutics's earnings and revenue compare to its market cap?
MDNA fundamental statistics
Market CapCA$94.03m
Earnings (TTM)-CA$22.58m
Revenue (TTM)n/a

0.0x

P/S Ratio

-4.2x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
MDNA income statement (TTM)
RevenueCA$0
Cost of RevenueCA$0
Gross ProfitCA$0
Other ExpensesCA$22.58m
Earnings-CA$22.58m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.40
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0.0%

How did MDNA perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is MDNA undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • PEG Ratio

Key Valuation Metric

Which metric is best to use when looking at relative valuation for MDNA?

Other financial metrics that can be useful for relative valuation.

MDNA key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenuen/a
Enterprise Value/EBITDA-3.3x
PEG Ration/a

Price to Book Ratio vs Peers

How does MDNA's PB Ratio compare to its peers?

MDNA PB Ratio vs Peers
The above table shows the PB ratio for MDNA vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPBEstimated GrowthMarket Cap
Peer Average13.9x
APS Aptose Biosciences
1.2x49.0%CA$98.7m
IMV IMV
5.2x22.2%CA$79.0m
EDT Spectral Medical
46.8x79.6%CA$100.6m
ONC Oncolytics Biotech
2.2x-0.4%CA$78.6m
MDNA Medicenna Therapeutics
4.5x58.4%CA$94.0m

Price-To-Book vs Peers: MDNA is good value based on its Price-To-Book Ratio (4.5x) compared to the peer average (13.9x).


Price to Earnings Ratio vs Industry

How does MDNA's PE Ratio compare vs other companies in the CA Biotechs Industry?

Price-To-Book vs Industry: MDNA is expensive based on its Price-To-Book Ratio (4.5x) compared to the Canadian Biotechs industry average (2.4x)


Price to Book Ratio vs Fair Ratio

What is MDNA's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

MDNA PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio4.5x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate MDNA's Price-To-Book Fair Ratio for valuation analysis.


Share Price vs Fair Value

What is the Fair Price of MDNA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate MDNA's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate MDNA's fair value for valuation analysis.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate MDNA's PEG Ratio to determine if it is good value.


Discover undervalued companies

Future Growth

How is Medicenna Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?

Future Growth Score

5/6

Future Growth Score 5/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


58.4%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: MDNA is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.6%).

Earnings vs Market: MDNA is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: MDNA is expected to become profitable in the next 3 years.

Revenue vs Market: MDNA's revenue (67.3% per year) is forecast to grow faster than the Canadian market (6.9% per year).

High Growth Revenue: MDNA's revenue (67.3% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if MDNA's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Past Performance

How has Medicenna Therapeutics performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-28.6%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: MDNA is currently unprofitable.

Growing Profit Margin: MDNA is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: MDNA is unprofitable, and losses have increased over the past 5 years at a rate of 28.6% per year.

Accelerating Growth: Unable to compare MDNA's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: MDNA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (95.6%).


Return on Equity

High ROE: MDNA has a negative Return on Equity (-108.36%), as it is currently unprofitable.


Discover strong past performing companies

Financial Health

How is Medicenna Therapeutics's financial position?

Financial Health Score

4/6

Financial Health Score 4/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: MDNA's short term assets (CA$23.4M) exceed its short term liabilities (CA$2.6M).

Long Term Liabilities: MDNA has no long term liabilities.


Debt to Equity History and Analysis

Debt Level: MDNA is debt free.

Reducing Debt: MDNA had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: MDNA has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: MDNA has less than a year of cash runway if free cash flow continues to reduce at historical rates of 23.9% each year


Discover healthy companies

Dividend

What is Medicenna Therapeutics's current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate MDNA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate MDNA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if MDNA's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if MDNA's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as MDNA has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

6.4yrs

Average management tenure


CEO

Fahar Merchant (64 yo)

10.67yrs

Tenure

CA$894,459

Compensation

Dr. Fahar Merchant, Ph.D. serves as the Chairman, Chief Executive Officer and President at A2 Acquisition Corp. Dr. Merchant has been President and Chief Executive Officer and Director of Medicenna Therape...


CEO Compensation Analysis

Compensation vs Market: Fahar's total compensation ($USD694.74K) is above average for companies of similar size in the Canadian market ($USD175.18K).

Compensation vs Earnings: Fahar's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: MDNA's management team is seasoned and experienced (6.4 years average tenure).


Board Members

Experienced Board: MDNA's board of directors are not considered experienced ( 1.3 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 5.1%.


Top Shareholders

Company Information

Medicenna Therapeutics Corp.'s employee growth, exchange listings and data sources


Key Information

  • Name: Medicenna Therapeutics Corp.
  • Ticker: MDNA
  • Exchange: TSX
  • Founded: 2017
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: CA$94.028m
  • Shares outstanding: 56.30m
  • Website: https://www.medicenna.com

Number of Employees


Location

  • Medicenna Therapeutics Corp.
  • 2 Bloor Street West
  • 7th Floor
  • Toronto
  • Ontario
  • M4W 3E2
  • Canada

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/06/27 00:00
End of Day Share Price2022/06/27 00:00
Earnings2022/03/31
Annual Earnings2022/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.